Antengene Corporation Limited (“ Antengene “, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma. In the first study ...

A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, ...

Andrew Moyens, 52, knew something was wrong when he was too tired to take down the Christmas tree - but little did he know at ...

A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment ...

Dr Oh added that about 80 per cent of such cases respond to conventional treatments such as chemotherapy and bone marrow ...

These patients had cancer that did not respond to chemotherapy or had relapsed after treatment. They had a less than 10 per ...

Research has shown that among patients with advanced non-small cell lung cancer, early palliative care delivered by video is ...

A new study reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment.

A new study published in Cell Reports Medicine reveals critical insights into the role of gamma-delta T cells across 33 ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today ...